Background: The frequency of small-bowel mucosal changes in patients with portal hypertension is not known. The objective of the study is to better define the mucosal abnormalities of portal hypertensive enteropathy (...Background: The frequency of small-bowel mucosal changes in patients with portal hypertension is not known. The objective of the study is to better define the mucosal abnormalities of portal hypertensive enteropathy (PHE) and to determine whether these findings are associated with the severity of liver disease, esophageal varices, portal gastropathy, portal colonopathy, or other clinical characteristics. Methods: We compared the medical records of 37 patients with cirrhosis and portal hypertension with 34 control patients who underwent capsule endoscopy over a 3- year period. Results: Mucosal changes were found to be significantly more common in the cirrhotic patients than in the control patients (67.5% vs. 0, p < 0.001). The lesions included telangiectasias or angiodysplastic-like lesions in 9 (24.3% ) patients, red spots in 23 (62.2% ), and varices in 3 (8.1% ). Active bleeding was seen during endoscopic examinations in 4 (10.8% ) patients. A comparison of patients with and those without PHE showed that grade 2+ or larger esophageal varices, portal gastropathy, portal colonopathy, and Child-Pugh class C cirrhosis were all significantly associated with PHE. There were no differences between these two groups of patients with regard to the etiology of cirrhosis, gender, or history of esophageal variceal bleeding. Conclusions: Mucosal abnormalities in portal jejunopathy include edema, erythema, and vascular lesions findings. A standardized grading system to classify the endoscopic appearance and the severity of portal enteropathy is proposed. The clinical import of these changes remains to be explained.展开更多
研究结肠腺癌活检组织中DNA 修复酶O 6-甲基鸟嘌呤-DNA甲基转移酶(O 6-methylguanine DNA methyltransferase,MGMT)和半乳糖凝集素-3(galectin-3,GAL-3)的表达及其与淋巴结转移的关系。方法:采用免疫组化(SP)法检测51例结肠腺癌、29例...研究结肠腺癌活检组织中DNA 修复酶O 6-甲基鸟嘌呤-DNA甲基转移酶(O 6-methylguanine DNA methyltransferase,MGMT)和半乳糖凝集素-3(galectin-3,GAL-3)的表达及其与淋巴结转移的关系。方法:采用免疫组化(SP)法检测51例结肠腺癌、29例转移淋巴结及51例炎性肠病组织中MGMT和galectin-3的表达,并分析MGMT和galectin-3的表达与结肠腺癌侵袭和淋巴结转移的关系以及二者之间的相关性。结果:MGMT在结肠腺癌、转移淋巴结及炎性肠病组织中的阳性率分别为58.82%(30/51)、17.24%(5/29)、78.43%(40/51),差异有统计学意义( P <0.05);galectin-3在结肠腺癌、转移淋巴结及炎性肠病组织中的阳性率分别为56.86%(29/51)、93.10%(27/29)、35.29%(18/51),差异有统计学意义( P <0.05)。在结肠腺癌中,MGMT和galectin-3的表达呈负相关( r =-0.327, P <0.05)。MGMT的低表达和galectin-3的高表达均与淋巴结转移有关( P <0.05)。结论:MGMT和galectin-3的异常表达可能与结肠腺癌的侵袭、转移有关,联合监测MGMT和galectin-3有望成为判断淋巴结转移更为有效的指标。展开更多
文摘Background: The frequency of small-bowel mucosal changes in patients with portal hypertension is not known. The objective of the study is to better define the mucosal abnormalities of portal hypertensive enteropathy (PHE) and to determine whether these findings are associated with the severity of liver disease, esophageal varices, portal gastropathy, portal colonopathy, or other clinical characteristics. Methods: We compared the medical records of 37 patients with cirrhosis and portal hypertension with 34 control patients who underwent capsule endoscopy over a 3- year period. Results: Mucosal changes were found to be significantly more common in the cirrhotic patients than in the control patients (67.5% vs. 0, p < 0.001). The lesions included telangiectasias or angiodysplastic-like lesions in 9 (24.3% ) patients, red spots in 23 (62.2% ), and varices in 3 (8.1% ). Active bleeding was seen during endoscopic examinations in 4 (10.8% ) patients. A comparison of patients with and those without PHE showed that grade 2+ or larger esophageal varices, portal gastropathy, portal colonopathy, and Child-Pugh class C cirrhosis were all significantly associated with PHE. There were no differences between these two groups of patients with regard to the etiology of cirrhosis, gender, or history of esophageal variceal bleeding. Conclusions: Mucosal abnormalities in portal jejunopathy include edema, erythema, and vascular lesions findings. A standardized grading system to classify the endoscopic appearance and the severity of portal enteropathy is proposed. The clinical import of these changes remains to be explained.
文摘研究结肠腺癌活检组织中DNA 修复酶O 6-甲基鸟嘌呤-DNA甲基转移酶(O 6-methylguanine DNA methyltransferase,MGMT)和半乳糖凝集素-3(galectin-3,GAL-3)的表达及其与淋巴结转移的关系。方法:采用免疫组化(SP)法检测51例结肠腺癌、29例转移淋巴结及51例炎性肠病组织中MGMT和galectin-3的表达,并分析MGMT和galectin-3的表达与结肠腺癌侵袭和淋巴结转移的关系以及二者之间的相关性。结果:MGMT在结肠腺癌、转移淋巴结及炎性肠病组织中的阳性率分别为58.82%(30/51)、17.24%(5/29)、78.43%(40/51),差异有统计学意义( P <0.05);galectin-3在结肠腺癌、转移淋巴结及炎性肠病组织中的阳性率分别为56.86%(29/51)、93.10%(27/29)、35.29%(18/51),差异有统计学意义( P <0.05)。在结肠腺癌中,MGMT和galectin-3的表达呈负相关( r =-0.327, P <0.05)。MGMT的低表达和galectin-3的高表达均与淋巴结转移有关( P <0.05)。结论:MGMT和galectin-3的异常表达可能与结肠腺癌的侵袭、转移有关,联合监测MGMT和galectin-3有望成为判断淋巴结转移更为有效的指标。
